Opinion|Videos|November 20, 2026

Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC

Fact checked by: Hannah Clarke

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

In this video, Jonathan E. Rosenberg, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, discusses the significance of the FDA approval of perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin (EV; Padcev) for patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC).1 He specifically touches on considerations for patient selection and comparisons with perioperative EV plus pembrolizumab (Keytruda).

Related to this article